nodes	percent_of_prediction	percent_of_DWPC	metapath
Nalbuphine—Warmth—Imiquimod—skin cancer	0.0513	0.0513	CcSEcCtD
Nalbuphine—Speech impairment NOS—Fluorouracil—skin cancer	0.0413	0.0413	CcSEcCtD
Nalbuphine—Feeling hot—Imiquimod—skin cancer	0.0208	0.0208	CcSEcCtD
Nalbuphine—Tingling sensation—Imiquimod—skin cancer	0.0203	0.0203	CcSEcCtD
Nalbuphine—Pulmonary oedema—Imiquimod—skin cancer	0.0145	0.0145	CcSEcCtD
Nalbuphine—Swelling—Imiquimod—skin cancer	0.0134	0.0134	CcSEcCtD
Nalbuphine—Dysgeusia—Vismodegib—skin cancer	0.0133	0.0133	CcSEcCtD
Nalbuphine—Muscle spasms—Vismodegib—skin cancer	0.013	0.013	CcSEcCtD
Nalbuphine—Speech disorder—Temozolomide—skin cancer	0.0114	0.0114	CcSEcCtD
Nalbuphine—Wheezing—Bleomycin—skin cancer	0.0113	0.0113	CcSEcCtD
Nalbuphine—Tingling sensation—Fluorouracil—skin cancer	0.0112	0.0112	CcSEcCtD
Nalbuphine—Numbness—Fluorouracil—skin cancer	0.0109	0.0109	CcSEcCtD
Nalbuphine—Speech disorder—Fluorouracil—skin cancer	0.0105	0.0105	CcSEcCtD
Nalbuphine—Sensory loss—Fluorouracil—skin cancer	0.0104	0.0104	CcSEcCtD
Nalbuphine—Sweating increased—Imiquimod—skin cancer	0.00998	0.00998	CcSEcCtD
Nalbuphine—Dyspepsia—Vismodegib—skin cancer	0.00973	0.00973	CcSEcCtD
Nalbuphine—Redness—Docetaxel—skin cancer	0.00964	0.00964	CcSEcCtD
Nalbuphine—Depression—Imiquimod—skin cancer	0.0091	0.0091	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Vismodegib—skin cancer	0.00904	0.00904	CcSEcCtD
Nalbuphine—Abdominal pain—Vismodegib—skin cancer	0.00874	0.00874	CcSEcCtD
Nalbuphine—Erythema—Vemurafenib—skin cancer	0.00837	0.00837	CcSEcCtD
Nalbuphine—Dysgeusia—Vemurafenib—skin cancer	0.00819	0.00819	CcSEcCtD
Nalbuphine—Asthenia—Vismodegib—skin cancer	0.00793	0.00793	CcSEcCtD
Nalbuphine—Pruritus—Vismodegib—skin cancer	0.00782	0.00782	CcSEcCtD
Nalbuphine—Euphoric mood—Fluorouracil—skin cancer	0.00774	0.00774	CcSEcCtD
Nalbuphine—Flushing—Imiquimod—skin cancer	0.00761	0.00761	CcSEcCtD
Nalbuphine—Swelling—Fluorouracil—skin cancer	0.00742	0.00742	CcSEcCtD
Nalbuphine—Bronchospasm—Bleomycin—skin cancer	0.00716	0.00716	CcSEcCtD
Nalbuphine—Erythema—Imiquimod—skin cancer	0.00714	0.00714	CcSEcCtD
Nalbuphine—Vomiting—Vismodegib—skin cancer	0.00703	0.00703	CcSEcCtD
Nalbuphine—Rash—Vismodegib—skin cancer	0.00697	0.00697	CcSEcCtD
Nalbuphine—Dermatitis—Vismodegib—skin cancer	0.00696	0.00696	CcSEcCtD
Nalbuphine—Nausea—Vismodegib—skin cancer	0.00657	0.00657	CcSEcCtD
Nalbuphine—Agitation—Imiquimod—skin cancer	0.00656	0.00656	CcSEcCtD
Nalbuphine—Injection site reaction—Docetaxel—skin cancer	0.00647	0.00647	CcSEcCtD
Nalbuphine—Syncope—Imiquimod—skin cancer	0.0064	0.0064	CcSEcCtD
Nalbuphine—Hypotension—Vemurafenib—skin cancer	0.00638	0.00638	CcSEcCtD
Nalbuphine—Loss of consciousness—Imiquimod—skin cancer	0.00627	0.00627	CcSEcCtD
Nalbuphine—Cardiac arrest—Fluorouracil—skin cancer	0.00622	0.00622	CcSEcCtD
Nalbuphine—Convulsion—Imiquimod—skin cancer	0.00618	0.00618	CcSEcCtD
Nalbuphine—Hypertension—Imiquimod—skin cancer	0.00616	0.00616	CcSEcCtD
Nalbuphine—Anxiety—Imiquimod—skin cancer	0.00605	0.00605	CcSEcCtD
Nalbuphine—Sweating increased—Temozolomide—skin cancer	0.00598	0.00598	CcSEcCtD
Nalbuphine—Dry mouth—Imiquimod—skin cancer	0.00594	0.00594	CcSEcCtD
Nalbuphine—Oedema—Imiquimod—skin cancer	0.00582	0.00582	CcSEcCtD
Nalbuphine—Hypoaesthesia—Bleomycin—skin cancer	0.00579	0.00579	CcSEcCtD
Nalbuphine—Pulmonary oedema—Docetaxel—skin cancer	0.00579	0.00579	CcSEcCtD
Nalbuphine—Shock—Imiquimod—skin cancer	0.00573	0.00573	CcSEcCtD
Nalbuphine—Tachycardia—Imiquimod—skin cancer	0.00568	0.00568	CcSEcCtD
Nalbuphine—Pollakiuria—Temozolomide—skin cancer	0.00567	0.00567	CcSEcCtD
Nalbuphine—Hyperhidrosis—Imiquimod—skin cancer	0.00563	0.00563	CcSEcCtD
Nalbuphine—Depression—Temozolomide—skin cancer	0.00546	0.00546	CcSEcCtD
Nalbuphine—Flushing—Bleomycin—skin cancer	0.0054	0.0054	CcSEcCtD
Nalbuphine—Body temperature increased—Vemurafenib—skin cancer	0.0054	0.0054	CcSEcCtD
Nalbuphine—Swelling—Docetaxel—skin cancer	0.00535	0.00535	CcSEcCtD
Nalbuphine—Paraesthesia—Imiquimod—skin cancer	0.00523	0.00523	CcSEcCtD
Nalbuphine—Dyspnoea—Imiquimod—skin cancer	0.00519	0.00519	CcSEcCtD
Nalbuphine—Somnolence—Imiquimod—skin cancer	0.00518	0.00518	CcSEcCtD
Nalbuphine—Dyspepsia—Imiquimod—skin cancer	0.00513	0.00513	CcSEcCtD
Nalbuphine—Erythema—Bleomycin—skin cancer	0.00507	0.00507	CcSEcCtD
Nalbuphine—Flushing—Dactinomycin—skin cancer	0.00504	0.00504	CcSEcCtD
Nalbuphine—Hypersensitivity—Vemurafenib—skin cancer	0.00503	0.00503	CcSEcCtD
Nalbuphine—Asthenia—Vemurafenib—skin cancer	0.0049	0.0049	CcSEcCtD
Nalbuphine—Hypoaesthesia—Temozolomide—skin cancer	0.00489	0.00489	CcSEcCtD
Nalbuphine—Hallucination—Temozolomide—skin cancer	0.00489	0.00489	CcSEcCtD
Nalbuphine—Pruritus—Vemurafenib—skin cancer	0.00483	0.00483	CcSEcCtD
Nalbuphine—Feeling abnormal—Imiquimod—skin cancer	0.0048	0.0048	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Imiquimod—skin cancer	0.00476	0.00476	CcSEcCtD
Nalbuphine—Erythema—Dactinomycin—skin cancer	0.00473	0.00473	CcSEcCtD
Nalbuphine—Urticaria—Imiquimod—skin cancer	0.00463	0.00463	CcSEcCtD
Nalbuphine—Body temperature increased—Imiquimod—skin cancer	0.0046	0.0046	CcSEcCtD
Nalbuphine—Abdominal pain—Imiquimod—skin cancer	0.0046	0.0046	CcSEcCtD
Nalbuphine—Flushing—Temozolomide—skin cancer	0.00456	0.00456	CcSEcCtD
Nalbuphine—Dizziness—Vemurafenib—skin cancer	0.00452	0.00452	CcSEcCtD
Nalbuphine—Hypoaesthesia—Fluorouracil—skin cancer	0.0045	0.0045	CcSEcCtD
Nalbuphine—Vomiting—Vemurafenib—skin cancer	0.00434	0.00434	CcSEcCtD
Nalbuphine—Rash—Vemurafenib—skin cancer	0.00431	0.00431	CcSEcCtD
Nalbuphine—Dermatitis—Vemurafenib—skin cancer	0.0043	0.0043	CcSEcCtD
Nalbuphine—Hypersensitivity—Imiquimod—skin cancer	0.00429	0.00429	CcSEcCtD
Nalbuphine—Headache—Vemurafenib—skin cancer	0.00428	0.00428	CcSEcCtD
Nalbuphine—Erythema—Temozolomide—skin cancer	0.00428	0.00428	CcSEcCtD
Nalbuphine—Cramp muscle—Docetaxel—skin cancer	0.00425	0.00425	CcSEcCtD
Nalbuphine—Dysgeusia—Temozolomide—skin cancer	0.00419	0.00419	CcSEcCtD
Nalbuphine—Asthenia—Imiquimod—skin cancer	0.00418	0.00418	CcSEcCtD
Nalbuphine—Confusional state—Bleomycin—skin cancer	0.00417	0.00417	CcSEcCtD
Nalbuphine—Oedema—Bleomycin—skin cancer	0.00414	0.00414	CcSEcCtD
Nalbuphine—Pruritus—Imiquimod—skin cancer	0.00412	0.00412	CcSEcCtD
Nalbuphine—Nausea—Vemurafenib—skin cancer	0.00406	0.00406	CcSEcCtD
Nalbuphine—Vision blurred—Temozolomide—skin cancer	0.00403	0.00403	CcSEcCtD
Nalbuphine—Bronchospasm—Docetaxel—skin cancer	0.00401	0.00401	CcSEcCtD
Nalbuphine—Tremor—Temozolomide—skin cancer	0.00401	0.00401	CcSEcCtD
Nalbuphine—Erythema—Fluorouracil—skin cancer	0.00394	0.00394	CcSEcCtD
Nalbuphine—Agitation—Temozolomide—skin cancer	0.00393	0.00393	CcSEcCtD
Nalbuphine—Hypotension—Bleomycin—skin cancer	0.00387	0.00387	CcSEcCtD
Nalbuphine—Oedema—Dactinomycin—skin cancer	0.00386	0.00386	CcSEcCtD
Nalbuphine—Dizziness—Imiquimod—skin cancer	0.00385	0.00385	CcSEcCtD
Nalbuphine—Vertigo—Temozolomide—skin cancer	0.00384	0.00384	CcSEcCtD
Nalbuphine—Paraesthesia—Bleomycin—skin cancer	0.00371	0.00371	CcSEcCtD
Nalbuphine—Vision blurred—Fluorouracil—skin cancer	0.00371	0.00371	CcSEcCtD
Nalbuphine—Convulsion—Temozolomide—skin cancer	0.0037	0.0037	CcSEcCtD
Nalbuphine—Vomiting—Imiquimod—skin cancer	0.0037	0.0037	CcSEcCtD
Nalbuphine—Hypertension—Temozolomide—skin cancer	0.00369	0.00369	CcSEcCtD
Nalbuphine—Dyspnoea—Bleomycin—skin cancer	0.00369	0.00369	CcSEcCtD
Nalbuphine—Rash—Imiquimod—skin cancer	0.00367	0.00367	CcSEcCtD
Nalbuphine—Dermatitis—Imiquimod—skin cancer	0.00367	0.00367	CcSEcCtD
Nalbuphine—Headache—Imiquimod—skin cancer	0.00365	0.00365	CcSEcCtD
Nalbuphine—Anxiety—Temozolomide—skin cancer	0.00363	0.00363	CcSEcCtD
Nalbuphine—Dry mouth—Temozolomide—skin cancer	0.00356	0.00356	CcSEcCtD
Nalbuphine—Confusional state—Temozolomide—skin cancer	0.00352	0.00352	CcSEcCtD
Nalbuphine—Oedema—Temozolomide—skin cancer	0.00349	0.00349	CcSEcCtD
Nalbuphine—Nausea—Imiquimod—skin cancer	0.00346	0.00346	CcSEcCtD
Nalbuphine—Convulsion—Fluorouracil—skin cancer	0.00341	0.00341	CcSEcCtD
Nalbuphine—Feeling abnormal—Bleomycin—skin cancer	0.00341	0.00341	CcSEcCtD
Nalbuphine—Hyperhidrosis—Temozolomide—skin cancer	0.00337	0.00337	CcSEcCtD
Nalbuphine—Urticaria—Bleomycin—skin cancer	0.00329	0.00329	CcSEcCtD
Nalbuphine—Body temperature increased—Bleomycin—skin cancer	0.00327	0.00327	CcSEcCtD
Nalbuphine—Hypoaesthesia—Docetaxel—skin cancer	0.00325	0.00325	CcSEcCtD
Nalbuphine—Confusional state—Fluorouracil—skin cancer	0.00324	0.00324	CcSEcCtD
Nalbuphine—Oedema—Fluorouracil—skin cancer	0.00322	0.00322	CcSEcCtD
Nalbuphine—Feeling abnormal—Dactinomycin—skin cancer	0.00318	0.00318	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Dactinomycin—skin cancer	0.00316	0.00316	CcSEcCtD
Nalbuphine—Tachycardia—Fluorouracil—skin cancer	0.00314	0.00314	CcSEcCtD
Nalbuphine—Paraesthesia—Temozolomide—skin cancer	0.00313	0.00313	CcSEcCtD
Nalbuphine—Dyspnoea—Temozolomide—skin cancer	0.00311	0.00311	CcSEcCtD
Nalbuphine—Somnolence—Temozolomide—skin cancer	0.0031	0.0031	CcSEcCtD
Nalbuphine—Dyspepsia—Temozolomide—skin cancer	0.00307	0.00307	CcSEcCtD
Nalbuphine—Abdominal pain—Dactinomycin—skin cancer	0.00305	0.00305	CcSEcCtD
Nalbuphine—Body temperature increased—Dactinomycin—skin cancer	0.00305	0.00305	CcSEcCtD
Nalbuphine—Hypersensitivity—Bleomycin—skin cancer	0.00305	0.00305	CcSEcCtD
Nalbuphine—Flushing—Docetaxel—skin cancer	0.00303	0.00303	CcSEcCtD
Nalbuphine—Hypotension—Fluorouracil—skin cancer	0.003	0.003	CcSEcCtD
Nalbuphine—Asthenia—Bleomycin—skin cancer	0.00297	0.00297	CcSEcCtD
Nalbuphine—Pruritus—Bleomycin—skin cancer	0.00293	0.00293	CcSEcCtD
Nalbuphine—Paraesthesia—Fluorouracil—skin cancer	0.00289	0.00289	CcSEcCtD
Nalbuphine—Feeling abnormal—Temozolomide—skin cancer	0.00288	0.00288	CcSEcCtD
Nalbuphine—Dyspnoea—Fluorouracil—skin cancer	0.00287	0.00287	CcSEcCtD
Nalbuphine—Somnolence—Fluorouracil—skin cancer	0.00286	0.00286	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Temozolomide—skin cancer	0.00285	0.00285	CcSEcCtD
Nalbuphine—Erythema—Docetaxel—skin cancer	0.00284	0.00284	CcSEcCtD
Nalbuphine—Hypersensitivity—Dactinomycin—skin cancer	0.00284	0.00284	CcSEcCtD
Nalbuphine—Dyspepsia—Fluorouracil—skin cancer	0.00283	0.00283	CcSEcCtD
Nalbuphine—Dysgeusia—Docetaxel—skin cancer	0.00278	0.00278	CcSEcCtD
Nalbuphine—Urticaria—Temozolomide—skin cancer	0.00277	0.00277	CcSEcCtD
Nalbuphine—Asthenia—Dactinomycin—skin cancer	0.00277	0.00277	CcSEcCtD
Nalbuphine—Body temperature increased—Temozolomide—skin cancer	0.00276	0.00276	CcSEcCtD
Nalbuphine—Abdominal pain—Temozolomide—skin cancer	0.00276	0.00276	CcSEcCtD
Nalbuphine—Muscle spasms—Docetaxel—skin cancer	0.00273	0.00273	CcSEcCtD
Nalbuphine—Feeling abnormal—Fluorouracil—skin cancer	0.00265	0.00265	CcSEcCtD
Nalbuphine—Vomiting—Bleomycin—skin cancer	0.00263	0.00263	CcSEcCtD
Nalbuphine—Rash—Bleomycin—skin cancer	0.00261	0.00261	CcSEcCtD
Nalbuphine—Dermatitis—Bleomycin—skin cancer	0.00261	0.00261	CcSEcCtD
Nalbuphine—Hypersensitivity—Temozolomide—skin cancer	0.00257	0.00257	CcSEcCtD
Nalbuphine—Urticaria—Fluorouracil—skin cancer	0.00255	0.00255	CcSEcCtD
Nalbuphine—Syncope—Docetaxel—skin cancer	0.00255	0.00255	CcSEcCtD
Nalbuphine—Body temperature increased—Fluorouracil—skin cancer	0.00254	0.00254	CcSEcCtD
Nalbuphine—Asthenia—Temozolomide—skin cancer	0.0025	0.0025	CcSEcCtD
Nalbuphine—Loss of consciousness—Docetaxel—skin cancer	0.0025	0.0025	CcSEcCtD
Nalbuphine—Pruritus—Temozolomide—skin cancer	0.00247	0.00247	CcSEcCtD
Nalbuphine—Convulsion—Docetaxel—skin cancer	0.00246	0.00246	CcSEcCtD
Nalbuphine—Nausea—Bleomycin—skin cancer	0.00246	0.00246	CcSEcCtD
Nalbuphine—Hypertension—Docetaxel—skin cancer	0.00246	0.00246	CcSEcCtD
Nalbuphine—Vomiting—Dactinomycin—skin cancer	0.00245	0.00245	CcSEcCtD
Nalbuphine—Rash—Dactinomycin—skin cancer	0.00243	0.00243	CcSEcCtD
Nalbuphine—Hypersensitivity—Fluorouracil—skin cancer	0.00237	0.00237	CcSEcCtD
Nalbuphine—Dry mouth—Docetaxel—skin cancer	0.00237	0.00237	CcSEcCtD
Nalbuphine—Confusional state—Docetaxel—skin cancer	0.00234	0.00234	CcSEcCtD
Nalbuphine—Oedema—Docetaxel—skin cancer	0.00232	0.00232	CcSEcCtD
Nalbuphine—Dizziness—Temozolomide—skin cancer	0.00231	0.00231	CcSEcCtD
Nalbuphine—Nausea—Dactinomycin—skin cancer	0.00229	0.00229	CcSEcCtD
Nalbuphine—Shock—Docetaxel—skin cancer	0.00228	0.00228	CcSEcCtD
Nalbuphine—Pruritus—Fluorouracil—skin cancer	0.00227	0.00227	CcSEcCtD
Nalbuphine—Tachycardia—Docetaxel—skin cancer	0.00226	0.00226	CcSEcCtD
Nalbuphine—Vomiting—Temozolomide—skin cancer	0.00222	0.00222	CcSEcCtD
Nalbuphine—Rash—Temozolomide—skin cancer	0.0022	0.0022	CcSEcCtD
Nalbuphine—Dermatitis—Temozolomide—skin cancer	0.0022	0.0022	CcSEcCtD
Nalbuphine—Headache—Temozolomide—skin cancer	0.00219	0.00219	CcSEcCtD
Nalbuphine—Hypotension—Docetaxel—skin cancer	0.00217	0.00217	CcSEcCtD
Nalbuphine—Dizziness—Fluorouracil—skin cancer	0.00213	0.00213	CcSEcCtD
Nalbuphine—Paraesthesia—Docetaxel—skin cancer	0.00208	0.00208	CcSEcCtD
Nalbuphine—Nausea—Temozolomide—skin cancer	0.00207	0.00207	CcSEcCtD
Nalbuphine—Dyspnoea—Docetaxel—skin cancer	0.00207	0.00207	CcSEcCtD
Nalbuphine—Somnolence—Docetaxel—skin cancer	0.00206	0.00206	CcSEcCtD
Nalbuphine—Vomiting—Fluorouracil—skin cancer	0.00204	0.00204	CcSEcCtD
Nalbuphine—Dyspepsia—Docetaxel—skin cancer	0.00204	0.00204	CcSEcCtD
Nalbuphine—Rash—Fluorouracil—skin cancer	0.00203	0.00203	CcSEcCtD
Nalbuphine—Dermatitis—Fluorouracil—skin cancer	0.00203	0.00203	CcSEcCtD
Nalbuphine—Headache—Fluorouracil—skin cancer	0.00201	0.00201	CcSEcCtD
Nalbuphine—Feeling abnormal—Docetaxel—skin cancer	0.00191	0.00191	CcSEcCtD
Nalbuphine—Nausea—Fluorouracil—skin cancer	0.00191	0.00191	CcSEcCtD
Nalbuphine—Gastrointestinal pain—Docetaxel—skin cancer	0.0019	0.0019	CcSEcCtD
Nalbuphine—Abdominal pain—Docetaxel—skin cancer	0.00183	0.00183	CcSEcCtD
Nalbuphine—Body temperature increased—Docetaxel—skin cancer	0.00183	0.00183	CcSEcCtD
Nalbuphine—Hypersensitivity—Docetaxel—skin cancer	0.00171	0.00171	CcSEcCtD
Nalbuphine—Asthenia—Docetaxel—skin cancer	0.00167	0.00167	CcSEcCtD
Nalbuphine—Pruritus—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Nalbuphine—Dizziness—Docetaxel—skin cancer	0.00153	0.00153	CcSEcCtD
Nalbuphine—Vomiting—Docetaxel—skin cancer	0.00148	0.00148	CcSEcCtD
Nalbuphine—Rash—Docetaxel—skin cancer	0.00146	0.00146	CcSEcCtD
Nalbuphine—Dermatitis—Docetaxel—skin cancer	0.00146	0.00146	CcSEcCtD
Nalbuphine—Headache—Docetaxel—skin cancer	0.00145	0.00145	CcSEcCtD
Nalbuphine—Nausea—Docetaxel—skin cancer	0.00138	0.00138	CcSEcCtD
